AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.64+6.24 (+5.70%) ▲|ACN266.76+12.20 (+4.79%) ▲|ADBE249.53+3.39 (+1.38%) ▲|AMAT365.00-16.92 (-4.43%) ▼|AMD484.19+0.29 (+0.06%) ▲|AMGN480.01+18.75 (+4.07%) ▲|AMT194.30+7.01 (+3.74%) ▲|AMZN268.12+17.43 (+6.95%) ▲|AVGO325.99-6.14 (-1.85%) ▼|AXP331.86+6.36 (+1.95%) ▲|BA176.72+3.41 (+1.96%) ▲|BAC51.35+1.69 (+3.40%) ▲|BKNG171.18+15.51 (+9.96%) ▲|BLK1,220.85+59.53 (+5.13%) ▲|BMY63.55+1.84 (+2.98%) ▲|BNY151.85+2.54 (+1.70%) ▲|BRK-B578.83+21.76 (+3.91%) ▲|C124.53+1.82 (+1.48%) ▲|CAT589.23-34.71 (-5.56%) ▼|CL98.68+3.06 (+3.20%) ▲|CMCSA24.55+0.88 (+3.70%) ▲|COF207.14-1.57 (-0.75%) ▼|COP135.86-8.54 (-5.91%) ▼|COST1,049.28+30.02 (+2.95%) ▲|CRM227.99+5.79 (+2.61%) ▲|CSCO103.09+0.12 (+0.12%) ▲|CVS80.93-10.48 (-11.46%) ▼|CVX216.80-8.48 (-3.76%) ▼|DE676.75+10.92 (+1.64%) ▲|DHR235.62+5.51 (+2.39%) ▲|DIS118.83+4.65 (+4.07%) ▲|DUK129.69+3.18 (+2.51%) ▲|EMR170.56+4.17 (+2.50%) ▲|FDX327.54+9.52 (+2.99%) ▲|GD365.18-9.32 (-2.49%) ▼|GE328.00+7.33 (+2.29%) ▲|GEV831.04-87.16 (-9.49%) ▼|GILD174.85+7.38 (+4.41%) ▲|GM92.19+3.85 (+4.36%) ▲|GOOG289.45+11.18 (+4.02%) ▲|GOOGL291.13+11.10 (+3.96%) ▲|GS927.52+31.43 (+3.51%) ▲|HD354.31+20.65 (+6.19%) ▲|HON227.47+3.42 (+1.53%) ▲|IBM255.06+5.02 (+2.01%) ▲|INTC57.95-2.60 (-4.29%) ▼|INTU359.05+14.33 (+4.16%) ▲|ISRG484.44+43.69 (+9.91%) ▲|JNJ276.55+10.38 (+3.90%) ▲|JPM350.66+12.68 (+3.75%) ▲|KO96.22+1.42 (+1.49%) ▲|LIN524.66+13.11 (+2.56%) ▲|LLY1,418.13+8.75 (+0.62%) ▲|LMT595.51-43.50 (-6.81%) ▼|LOW228.90+15.52 (+7.27%) ▲|LRCX219.64-11.09 (-4.80%) ▼|MA671.34+24.16 (+3.73%) ▲|MCD279.21+16.17 (+6.15%) ▲|MDLZ67.39+2.27 (+3.49%) ▲|MDT105.33+6.45 (+6.52%) ▲|META630.50+9.47 (+1.52%) ▲|MMM194.15+17.10 (+9.66%) ▲|MO77.80+0.86 (+1.12%) ▲|MRK149.22+4.55 (+3.15%) ▲|MS192.90+6.81 (+3.66%) ▲|MSFT558.97+37.98 (+7.29%) ▲|MU796.53-58.57 (-6.85%) ▼|NEE88.43+4.10 (+4.86%) ▲|NFLX66.49+3.07 (+4.83%) ▲|NKE40.18+1.70 (+4.42%) ▲|NOW110.43+1.27 (+1.16%) ▲|NVDA202.27-4.42 (-2.14%) ▼|ORCL124.23-1.96 (-1.55%) ▼|PEP142.67+5.40 (+3.93%) ▲|PFE30.73+0.73 (+2.42%) ▲|PG167.27+5.21 (+3.21%) ▲|PLTR172.47-2.93 (-1.67%) ▼|PM210.21+2.18 (+1.05%) ▲|QCOM165.06+0.63 (+0.38%) ▲|RTX197.28-6.54 (-3.21%) ▼|SBUX108.70+3.93 (+3.75%) ▲|SCHW93.59+4.31 (+4.82%) ▲|SO93.31-0.44 (-0.47%) ▼|SPG227.99+5.91 (+2.66%) ▲|T21.71+0.32 (+1.51%) ▲|TMO706.49+8.15 (+1.17%) ▲|TMUS158.27+3.86 (+2.50%) ▲|TSLA386.61-11.90 (-2.98%) ▼|TXN310.48-2.01 (-0.64%) ▼|UBER70.43+3.83 (+5.75%) ▲|UNH414.63+10.19 (+2.52%) ▲|UNP308.06+4.63 (+1.53%) ▲|UPS114.27+5.10 (+4.67%) ▲|USB60.84+0.95 (+1.58%) ▲|V434.64+14.22 (+3.38%) ▲|VZ46.11+0.87 (+1.92%) ▲|WFC87.42+1.89 (+2.20%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM169.40-8.06 (-4.54%) ▼|AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.64+6.24 (+5.70%) ▲|ACN266.76+12.20 (+4.79%) ▲|ADBE249.53+3.39 (+1.38%) ▲|AMAT365.00-16.92 (-4.43%) ▼|AMD484.19+0.29 (+0.06%) ▲|AMGN480.01+18.75 (+4.07%) ▲|AMT194.30+7.01 (+3.74%) ▲|AMZN268.12+17.43 (+6.95%) ▲|AVGO325.99-6.14 (-1.85%) ▼|AXP331.86+6.36 (+1.95%) ▲|BA176.72+3.41 (+1.96%) ▲|BAC51.35+1.69 (+3.40%) ▲|BKNG171.18+15.51 (+9.96%) ▲|BLK1,220.85+59.53 (+5.13%) ▲|BMY63.55+1.84 (+2.98%) ▲|BNY151.85+2.54 (+1.70%) ▲|BRK-B578.83+21.76 (+3.91%) ▲|C124.53+1.82 (+1.48%) ▲|CAT589.23-34.71 (-5.56%) ▼|CL98.68+3.06 (+3.20%) ▲|CMCSA24.55+0.88 (+3.70%) ▲|COF207.14-1.57 (-0.75%) ▼|COP135.86-8.54 (-5.91%) ▼|COST1,049.28+30.02 (+2.95%) ▲|CRM227.99+5.79 (+2.61%) ▲|CSCO103.09+0.12 (+0.12%) ▲|CVS80.93-10.48 (-11.46%) ▼|CVX216.80-8.48 (-3.76%) ▼|DE676.75+10.92 (+1.64%) ▲|DHR235.62+5.51 (+2.39%) ▲|DIS118.83+4.65 (+4.07%) ▲|DUK129.69+3.18 (+2.51%) ▲|EMR170.56+4.17 (+2.50%) ▲|FDX327.54+9.52 (+2.99%) ▲|GD365.18-9.32 (-2.49%) ▼|GE328.00+7.33 (+2.29%) ▲|GEV831.04-87.16 (-9.49%) ▼|GILD174.85+7.38 (+4.41%) ▲|GM92.19+3.85 (+4.36%) ▲|GOOG289.45+11.18 (+4.02%) ▲|GOOGL291.13+11.10 (+3.96%) ▲|GS927.52+31.43 (+3.51%) ▲|HD354.31+20.65 (+6.19%) ▲|HON227.47+3.42 (+1.53%) ▲|IBM255.06+5.02 (+2.01%) ▲|INTC57.95-2.60 (-4.29%) ▼|INTU359.05+14.33 (+4.16%) ▲|ISRG484.44+43.69 (+9.91%) ▲|JNJ276.55+10.38 (+3.90%) ▲|JPM350.66+12.68 (+3.75%) ▲|KO96.22+1.42 (+1.49%) ▲|LIN524.66+13.11 (+2.56%) ▲|LLY1,418.13+8.75 (+0.62%) ▲|LMT595.51-43.50 (-6.81%) ▼|LOW228.90+15.52 (+7.27%) ▲|LRCX219.64-11.09 (-4.80%) ▼|MA671.34+24.16 (+3.73%) ▲|MCD279.21+16.17 (+6.15%) ▲|MDLZ67.39+2.27 (+3.49%) ▲|MDT105.33+6.45 (+6.52%) ▲|META630.50+9.47 (+1.52%) ▲|MMM194.15+17.10 (+9.66%) ▲|MO77.80+0.86 (+1.12%) ▲|MRK149.22+4.55 (+3.15%) ▲|MS192.90+6.81 (+3.66%) ▲|MSFT558.97+37.98 (+7.29%) ▲|MU796.53-58.57 (-6.85%) ▼|NEE88.43+4.10 (+4.86%) ▲|NFLX66.49+3.07 (+4.83%) ▲|NKE40.18+1.70 (+4.42%) ▲|NOW110.43+1.27 (+1.16%) ▲|NVDA202.27-4.42 (-2.14%) ▼|ORCL124.23-1.96 (-1.55%) ▼|PEP142.67+5.40 (+3.93%) ▲|PFE30.73+0.73 (+2.42%) ▲|PG167.27+5.21 (+3.21%) ▲|PLTR172.47-2.93 (-1.67%) ▼|PM210.21+2.18 (+1.05%) ▲|QCOM165.06+0.63 (+0.38%) ▲|RTX197.28-6.54 (-3.21%) ▼|SBUX108.70+3.93 (+3.75%) ▲|SCHW93.59+4.31 (+4.82%) ▲|SO93.31-0.44 (-0.47%) ▼|SPG227.99+5.91 (+2.66%) ▲|T21.71+0.32 (+1.51%) ▲|TMO706.49+8.15 (+1.17%) ▲|TMUS158.27+3.86 (+2.50%) ▲|TSLA386.61-11.90 (-2.98%) ▼|TXN310.48-2.01 (-0.64%) ▼|UBER70.43+3.83 (+5.75%) ▲|UNH414.63+10.19 (+2.52%) ▲|UNP308.06+4.63 (+1.53%) ▲|UPS114.27+5.10 (+4.67%) ▲|USB60.84+0.95 (+1.58%) ▲|V434.64+14.22 (+3.38%) ▲|VZ46.11+0.87 (+1.92%) ▲|WFC87.42+1.89 (+2.20%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM169.40-8.06 (-4.54%) ▼|
20.1 C
New York
Wednesday, November 4, 2026

Tag: Complex

newsFORsourcecompanycontentinformationreleases1market

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

Jacob Wang Featured in XYZ Media’s “Next Generation of Innovators” for Developing a Self-Actuated, Eco-Friendly Soft Robot for Drug Delivery

LOS ANGELES, June 22, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is proud to announce the latest feature in its “Next Generation of Innovators” series, a digital campaign celebrating extraordinary young minds developing innovative solutions to global challenges. The latest series highlights Jacob Wang from Bullis Charter School at Los Altos, CA, for engineering a novel self-actuated soft robot that operates without external power sources or electronics, designed with potential for drug delivery.

AI Integration Accelerates Mathematical Discovery Algorithms: Analyzing Computational Efficiency Gains

Artificial intelligence's capabilities have expanded across diverse domains, yet its proficiency in complex mathematical reasoning remains limited. Large language models, such as OpenAI's ChatGPT,...

Europe Plans Defense Splurge—Get Ready for Bureaucratic Ballet and Budget Black Holes.

Oh, look, Europe's finally decided it might need to do more than rely on Uncle Sam’s military might. With growth slowing and trade dropping...

Debt Consolidation Loan for Poor Credit Score: Radcred Instant Funding Solution with No Credit Check & Same-Day Loan

Simplify your finances by consolidating high-interest debt into one low-interest loan. Apply today with Radcred for fast relief and better financial management. 
Simplify your finances by consolidating high-interest debt into one low-interest loan. Apply today with Radcred for fast relief and better financial management.

BexBack Launches $50 Welcome Bonus and 100% Deposit Match to Empower Crypto Traders with 100x Leverage

SINGAPORE, June 21, 2025 (GLOBE NEWSWIRE) -- BexBack Exchange has launched an aggressive new promotion to empower both new and seasoned crypto traders: a $50 welcome bonus and a 100% deposit match for all new users. As the crypto market braces for another period of high volatility, BexBack is making futures trading more accessible and profitable than ever. With up to 100x leverage, zero KYC requirements, and support for over 50 digital assets, the platform provides an ideal environment for those seeking to capitalize on market swings without large upfront capital.

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Certified and Profitable: AIXA Miner Redefines Passive Crypto Income After FinCEN Approval

Colorado, USA, June 21, 2025 (GLOBE NEWSWIRE) -- Certified and profitable: AIXA Miner redefines passive crypto income following FinCEN approval

AIXA Miner, a leading crypto cloud mining platform, has officially secured its FinCEN Money Services Business (MSB) certification, becoming one of the few fully regulated mining platforms in the U.S. This regulatory milestone has rapidly boosted investor confidence—particularly among U.S. users—and helped expand AIXA Miner’s global user base to over 5 million active miners.

Analyzing Annuities’ Reputation: Evaluating Their Role in Strategic Financial Planning

Running out of money in retirement is a significant concern among investors, often surpassing even the fear of death. While maximizing contributions to an...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsComplex

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers